This is what a buyer checks before they shortlist pharma, medical and life sciences suppliers.
What does a partner check before licensing or sourcing biotech material?
They check the development stage and the data supporting it, the intellectual property position, and whether manufacturing can scale. Biotech partnering is an evidence and rights question, so stage-appropriate disclosure matters more than breadth of claim.
A business development team is assessing whether a programme is real enough and protected enough to justify a partnering conversation.
Last corpus review: 4 August 2026 · Written for biotechnology companys selling to business buyers
What does a partner check before licensing or sourcing biotech material?
What buyers check in pharma, medical and life sciences
Three things, in order: what the product is, what the paperwork proves, and when each document gets asked for.
Patent families, status and territories
Intellectual property summary
Asked at: partnering discussion — the core asset
The evidence supporting the current stage
Development stage data package
Asked at: due diligence
Quality systems appropriate to the developm…
Quality certification
Asked at: partner assessment
First, what the product is
The fields a buyer scans before deciding whether you are worth contacting. Missing one of them usually ends the visit without an email.
- 1
Technology platform and application
What the technology does and where it applies.
- 2
Development stage
Research, preclinical, clinical or commercial changes everything.
- 3
Intellectual property position
Patents granted, pending and their territories.
- 4
Manufacturing capability and scale
Whether the product can be made at commercial scale.
- 5
Regulatory pathway
The route and stage in each target market.
- 6
Quality systems in place
Determines readiness for regulated work.
- 7
Partnering model sought
Licensing, supply, co-development or acquisition.
Then the paperwork
Naming the documents you can issue is what separates a supplier who can be audited from one who cannot.
| Document | What it proves | Where it belongs |
|---|---|---|
| Intellectual property summaryAsked at: partnering discussion — the core asset | Patent families, status and territories | Name it, share on request |
| Development stage data packageAsked at: due diligence | The evidence supporting the current stage | Name it, share on request |
| Quality certificationAsked at: partner assessment | Quality systems appropriate to the development stage | Publish it |
| Manufacturing capability statementAsked at: commercial assessment | Scale achieved and scale achievable | Name it, share on request |
| Regulatory correspondence summaryAsked at: due diligence | Interactions and agreed pathway with authorities | Name it, share on request |
| Publication and peer review recordAsked at: credibility assessment | Independently reviewed evidence for the platform | Publish it |
| Material transfer and confidentiality termsAsked at: before any exchange | How material and data are shared before a deal | Publish it |
The shortlist moment
A buyer lines up a few suppliers and keeps the ones whose proof is easy to check. The rest get a closed tab, not an email.
The buyer asks: What does a partner check before licensing or sourcing biotech material?
A few suppliers get compared side by side:
A supplier with Quality certification on the page
Quality systems appropriate to the development stage
A supplier with Publication and peer review record on the page
Independently reviewed evidence for the platform
A supplier with Material transfer and confidentiality terms on the page
How material and data are shared before a deal
Is one of them you?
What Plact does for pharma, medical and life sciences suppliers
Four jobs, done on your site. Each one is a document buyers in this industry already ask for.
Put the Quality certification on the page buyers check
Quality systems appropriate to the development stage
Put the Publication and peer review record on the page buyers check
Independently reviewed evidence for the platform
Put the Material transfer and confidentiality terms on the page buyers check
How material and data are shared before a deal
Name the Intellectual property summary and share it on request
Patent families, status and territories
What a useful enquiry looks like
A form that collects these fields can be answered properly the first time. A form that collects a name and a message cannot.
Enquiry form · biotechnology
Enough to reply usefully, short enough that a buyer finishes it.
- Technology and application of interest
- Determines the fit.
- Partnering model sought
- Licensing, supply or co-development.
- Development stage required
- Partners have stage preferences.
- Territory and rights of interest
- Defines the deal shape.
- Technical due diligence needs
- What evidence will be required.
- Timeline and decision process
- Partnering timelines are long.
An enquiry from this search asks for
- Partnering model sought
- Timeline and decision process
- Technology and application of interest
- Development stage required
Questions suppliers ask
How much should a biotech company publish publicly?
Enough for a partner to determine fit and credibility: the platform, the application, the development stage, the publication record and the partnering model sought. The data package belongs behind confidentiality, but a site that says nothing specific cannot start a conversation either.
How should development stage be described?
Precisely and conservatively, using the standard terminology for the field. Partners assess risk by stage, and precision is read as competence. Ambiguity intended to make a programme look more advanced is detected quickly and remembered.
What role does the publication record play?
It is often the strongest public credibility signal available, because it is independently reviewed. Listing peer-reviewed publications lets a partner assess the science before contact, which is exactly what they want to do first.
Documents and standards named here are the ones buyers in this industry commonly ask for; requirements vary by market, customer and contract, so treat this as a starting checklist rather than a compliance list. Clearer pages can help discovery and evaluation. They do not guarantee rankings, AI citations, enquiries or revenue.
Plact Research. Plact's editorial desk for buyer-evidence research. Industry standards, documents and buyer questions are researched and drafted with Plact's AI tools, then reviewed by Praveen Kavuri before publication. Every claim cites the standard, regulation or public source it rests on.
Related buyer questions
- Pharma and ingredientsWhat does a formulator check before qualifying a new API or excipient supplier?
- Medical devicesWhat does a distributor check before taking on a medical device?
- Surgical instrumentsWhat does a hospital buyer check before approving surgical instruments?
- Waste managementWhat does a business check before appointing a waste contractor?
Get your free review
A free review of what a buyer finds when they look for pharma, medical and life sciences suppliers, and what to fix first.